Study shows Truvada reduces HIV infection

Researchers at the J. David Gladstone Institutes and colleagues said pre-exposure prophylaxis with once-daily oral Truvada emtricitabine/tenofovir met the primary endpoint of significantly reducing the incidence of HIV infection vs. placebo in the Phase III iPrEx trial in 2,499 HIV-seronegative men who have sex with men. At a median follow-up of 1.2 years, 36 men treated with Truvada developed cases of HIV infection compared to 64 men treated with placebo (p=0.005). Additionally, subjects who adhered to the daily Truvada regimen for 90% or more days had 73% fewer HIV infections compared to patients who did not adhere to the regimen (p<0.001). ...